# Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

> **NCT05724849** · PHASE2 · WITHDRAWN · sponsor: **Vanderbilt University Medical Center**

## Conditions studied

- Head and Neck Cancer
- Depression

## Interventions

- **DRUG:** Venlafaxine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05724849
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Issues with funding
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724849, "Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05724849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*